Evidence map›Paper›PMID 36839168›Full record

ArticleNutrients2023

Serum Fatty Acid Composition Balance by Fuzzy C-Means Method in Individuals with or without Metabolic Dysfunction-Associated Fatty Liver Disease.

Yuka Nagase, Takao Satoh, Keiichi Shigetome, Naoto Tokumaru, Erika Matsumoto, Kazunori D Yamada, Tadashi Imafuku, Hiroshi Watanabe, Toru Maruyama, Yasuhiro Ogata and 3 more

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Yuka NagaseDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
Takao SatohKumamoto Industrial Research Institute, Kumamoto 862-0901, Japan.
Keiichi ShigetomeDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
Naoto TokumaruDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
Erika MatsumotoDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
Kazunori D YamadaUnprecedented-Scale Data Analytics Center, Tohoku University, Sendai 980-8578, Japan.
Tadashi ImafukuDepartment of Molecular Pathophysiology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama 641-8509, Japan.
Hiroshi WatanabeDepartment of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.ORCID 0000-0001-9268-4144
Toru MaruyamaDepartment of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
Yasuhiro OgataJapanese Red Cross Kumamoto Health Care Center, Kumamoto 861-8520, Japan.
Minoru YoshidaJapanese Red Cross Kumamoto Health Care Center, Kumamoto 861-8520, Japan.
Junji SaruwatariDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.ORCID 0000-0001-6266-1347
Kentaro OnikiDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.ORCID 0000-0002-5926-7151
Kumamoto University · JPJapanese Red Cross Kumamoto Hospital · JPKumamoto Industrial Research Institute · JPTohoku University · JPWakayama Medical University · JP

Funding

Japan Society for the Promotion of Science 19K07166Japan Society for the Promotion of Science 20K07134Smoking Research Foundation NoneTakeda Science Foundation None
6 · The paper itself

Abstract

Circulating fatty acid composition is assumed to play an important role in metabolic dysfunction-associated fatty liver disease (MAFLD) pathogenesis. This study aimed to investigate the association between the overall balance of serum fatty acid composition and MAFLD prevalence. This cross-sectional study involved 400 Japanese individuals recruited from a health-screening program. We measured fatty acids in serum lipids using gas chromatography-mass spectrometry. The serum fatty acid composition balance was evaluated using fuzzy c-means clustering, which assigns individual data points to multiple clusters and calculates the percentage of data points belonging to multiple clusters, and serum fatty acid mass%. The participants were classified into four characteristic subclasses (i.e., Clusters 1, 2, 3, and 4), and the specific serum fatty acid composition balance (i.e., Cluster 4) was associated with a higher MAFLD prevalence. We suggest that the fuzzy c-means method can be used to determine the circulating fatty acid composition balance and highlight the importance of focusing on this balance when examining the relationship between MAFLD and serum fatty acids.

Indexed as

Fatty AcidsNon-alcoholic Fatty Liver DiseaseCluster AnalysisCross-Sectional StudiesGas Chromatography-Mass SpectrometryHumansFatty Acidsclusteringfatty acidfatty acid composition balancefuzzy c-means methodmetabolic dysfunction-associated fatty liver disease

Identifiers

PMID36839168
PMCPMC9960614
OpenAlexW4319298430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.